Nuvalent’s $350M offering; FDA lifts partial hold on Zentalis drug

Plus, news about As­cendis Phar­ma, Ko­r­ro Bio, No­vo Nordisk and Medexus:

Nu­va­lent of­fers $350M in shares: The on­col­o­gy biotech is look­ing to

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.